share_log

Aptinyx Inc. (NASDAQ:APTX) Expected to Post Q1 2024 Earnings of ($0.06) Per Share

Defense World ·  Apr 3, 2023 14:22

Aptinyx Inc. (NASDAQ:APTX – Get Rating) – William Blair issued their Q1 2024 EPS estimates for Aptinyx in a research note issued on Friday, March 31st. William Blair analyst M. Minter forecasts that the company will post earnings per share of ($0.06) for the quarter. The consensus estimate for Aptinyx's current full-year earnings is ($0.56) per share. William Blair also issued estimates for Aptinyx's Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at ($0.05) EPS and Q4 2024 earnings at ($0.04) EPS.

Get Aptinyx alerts:

A number of other research firms have also weighed in on APTX. SVB Leerink reissued a "market perform" rating and issued a $0.50 target price on shares of Aptinyx in a report on Wednesday, March 1st. HC Wainwright lowered shares of Aptinyx from a "buy" rating to a "neutral" rating in a report on Tuesday, March 7th. Finally, SVB Securities downgraded Aptinyx from an "outperform" rating to a "market perform" rating in a research report on Wednesday, March 1st. Eight research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $2.58.

Aptinyx Trading Down 6.5 %

APTX stock opened at $0.12 on Monday. The firm has a fifty day moving average price of $0.35 and a 200 day moving average price of $0.34. Aptinyx has a fifty-two week low of $0.12 and a fifty-two week high of $2.87. The company has a debt-to-equity ratio of 0.51, a quick ratio of 27.45 and a current ratio of 27.45. The firm has a market cap of $8.45 million, a PE ratio of -0.13 and a beta of 1.39.

Institutional Trading of Aptinyx

A number of institutional investors have recently bought and sold shares of APTX. Jane Street Group LLC lifted its position in shares of Aptinyx by 213.3% during the third quarter. Jane Street Group LLC now owns 105,771 shares of the company's stock worth $39,000 after purchasing an additional 72,006 shares during the last quarter. HBK Sorce Advisory LLC lifted its position in shares of Aptinyx by 100.0% during the fourth quarter. HBK Sorce Advisory LLC now owns 52,000 shares of the company's stock worth $53,000 after purchasing an additional 26,000 shares during the last quarter. Cetera Advisor Networks LLC bought a new stake in shares of Aptinyx during the first quarter worth $92,000. Renaissance Technologies LLC lifted its position in shares of Aptinyx by 14.3% during the fourth quarter. Renaissance Technologies LLC now owns 618,226 shares of the company's stock worth $176,000 after purchasing an additional 77,200 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Aptinyx by 13.5% during the first quarter. Dimensional Fund Advisors LP now owns 140,711 shares of the company's stock worth $320,000 after purchasing an additional 16,774 shares during the last quarter. 45.93% of the stock is currently owned by institutional investors.

Aptinyx Company Profile

(Get Rating)

Aptinyx Inc is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G.

Featured Stories

  • Get a free copy of the StockNews.com research report on Aptinyx (APTX)
  • MarketBeat Week in Review – 3/27 – 3/31
  • What is a Gold IRA, and is it a Viable Investment?
  • Is Braze Inc Ready To Rocket Higher?
  • Mullen Automotive Makes Deliveries; Short-Squeeze Possible
  • Can Frontline Maintain This Momentum?

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment